Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5686434 A
Publication typeGrant
Application numberUS 08/640,945
PCT numberPCT/IB1994/000313
Publication dateNov 11, 1997
Filing dateOct 12, 1994
Priority dateNov 26, 1993
Fee statusLapsed
Also published asCA2177375A1, DE69422061D1, DE69422061T2, EP0730587A1, EP0730587B1, WO1995014680A1
Publication number08640945, 640945, PCT/1994/313, PCT/IB/1994/000313, PCT/IB/1994/00313, PCT/IB/94/000313, PCT/IB/94/00313, PCT/IB1994/000313, PCT/IB1994/00313, PCT/IB1994000313, PCT/IB199400313, PCT/IB94/000313, PCT/IB94/00313, PCT/IB94000313, PCT/IB9400313, US 5686434 A, US 5686434A, US-A-5686434, US5686434 A, US5686434A
InventorsEdward Fox Kleinman
Original AssigneePfizer Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
3-aryl-2-isoxazolines as antiinflammatory agents
US 5686434 A
Abstract
This invention relates to 3-aryl-2-isoxazoline compounds which are selective inhibitors of phosphodiesterase type IV (PDEIV). The 3-aryl-2-isoxazolines are useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis and osteoarthritis. This invention also relates to pharmaceutical compositions useful therefor.
Images(20)
Previous page
Next page
Claims(16)
What is claimed is:
1. A compound of the formula ##STR28## the racemic, racemic-diastereomeric mixtures and optical isomers of said compound and the pharmaceutically acceptable salts thereof wherein
Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring;
R1 is alkyl having 1 to 3 carbons, fluoromethyl, difluoromethyl or trifluoromethyl;
R2 is (C3 -C7)cycloalkyl, optionally substituted phenylalkyl having 1 to 6 carbons in the alkyl portion or bicycloalkyl having 6 to 9 carbons;
wherein the aromatic portion of the optionally substituted phenylalkyl is optionally independently substituted with (C1 -C4) alkyl, (C1 -C4) alkoxy, halogen or CF3 ;
R3 is hydrogen, (C1 -C3)alkyl, mono-hydroxyalkyl having 1 to 3 carbons or alkoxyalkyl having 1 to 3 carbons in the alkyl portion and 1 to 3 carbons in the alkoxy portion;
R4 is hydrogen, (C1 -C5)alkyl, --COOH, alkoxyalkyl having 1 to 3 carbons in the alkyl portion and 1 to 3 carbons in the alkoxy portion, N-alkylaminoalkyl having 1 to 3 carbons in the alkylamino portion and 1 to 3 carbons in the alkyl portion or N,N-dialkylaminoalkyl having a total of 2 to 6 carbons in the dialkylamino portion and 1 to 3 carbons in the alkyl portion;
or R3 and R4 are taken together with the carbon atoms to which they are attached and form --CH2 OCH2 OCH2 --; and
R5 is hydrogen, --CHO, amino, aminoalkyl having 1 to 3 carbons, ##STR29## mono-hydroxyalkyl having 1 to 3 carbons, --(CH2)b --COOR6, --COR7, --(CH2)m CO2 H, (C1 -C4) alkyl, hydroxy, --(CH2)q CONX2 X3, --(CH2)r SO2 NX4 X5, --(CH2)s PO3 H2 or ##STR30## wherein b is 0 or an integer from 1 to 6; m, n, q, r, s and t are independently 0, 1, 2, 3 or 4;
R6 and R7 are each independently (C1 -C4)alkyl;
X1 is hydrogen, (C1 -C4) alkyl, --O(C1 -C4) alkyl or alkoxyphenyl having one to four carbon atoms in the alkoxy portion;
X2, X3, X4 and X5 are each independently hydrogen or (C1 -C3) alkyl; and
X6 is (C1 -C3)alkyl or phenyl;
provided that when R4 is --COOH then R5 is not --COOH.
2. A compound according to claim 1 wherein R1 is methyl; R2 is (C3 -C7)cycloalkyl, bicycloalkyl having 6 to 9 carbons, or phenylalkyl having 1 to 6 carbons in the alkyl portion; R3 is hydrogen or (C1 -C3)alkyl; R4 is hydrogen or (C1 -C5)alkyl and R5 is --(CH2)m CO2 H, --CHO, --COCH3, amino, hydroxy, mono-hydroxyalkyl having 1 to 3 carbons, aminoalkyl having 1 to 3 carbons, or ##STR31## wherein X1 is (C1 -C4)alkyl or alkoxyphenyl having one to four carbon atoms in the alkoxy portion and n is 0 or an integer from 1 to 3.
3. A compound according to claim 2 wherein R2 is cyclopentyl or phenylalkyl having 4 or 5 carbons in the alkyl portion.
4. A compound according to claim 3 wherein R2 is 5-phenylpentyl.
5. A compound according to claim 4 wherein R5 is --(CH2)m CO2 H, --CHO, --COCH3, hydroxy or mono-hydroxyalkyl having 1 to 3 carbons.
6. A compound according to claim 5 wherein R5 is --(CH2)m CO2 H.
7. A compound according to claim 6 wherein R5 is hydrogen; R4 is hydrogen or (C1 -C5)alkyl and m=0.
8. A compound according to claim 7 wherein R4 is hydrogen, methyl, ethyl or propyl.
9. A compound according to claim 8 wherein the compound is (+) or (-)-5-ethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!-phenyl-2-isoxazoline-5-carboxylic acid.
10. A compound according to claim 9 wherein the compound is (-)-5-ethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic acid.
11. A compound according to claim 1 wherein R is CH3 ; R is 5-phenyl-pentyl; R3 is hydrogen; R4 is hydrogen or CH3 and R5 is --(CH2)s PO3 H2 wherein s is 0 or 1.
12. A compound according to claim 1 wherein R1 is CH3 ; R2 is cyclopentyl; R3 is hydrogen; R4 is hydrogen and R5 is --(CH2)s PO3 H2 wherein s is 0.
13. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable diluent or carrier.
14. A method of inhibiting phosphodiesterase type IV in a mammal in need thereof which comprises administering to said mammal a phosphodiesterase IV inhibiting amount of a compound according to claim 1.
15. A method of treating an inflammatory condition in a mammal in need thereof which comprises administering to said mammal an antiinflammatory amount of a compound according to claim 1.
16. A method of treating AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis or shock in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound according to claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS

This application is the national stage of PCT Application No. PCT/IB94/00313 having an international filing date of Oct. 12, 1994, which is a continuation of U.S. application Ser. No. 08/157,241, filed Nov. 26, 1993, now abandoned.

BACKGROUND OF THE INVENTION

This invention relates to a series of 3-aryl-2-isoxazoline compounds which are selective inhibitors of phosphodiesterase (PDE) type IV and as such are useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases.

This invention also relates to the pharmaceutically acceptable salts of said compounds; to a method of using such compounds in inhibiting PDEIV, the treatment of inflammatory conditions and the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis and dermatitis in mammals, especially humans; and to pharmaceutical compositions useful therefor.

The "inflammatory conditions" which can be treated according to this invention include, but are not limited to, chronic obstructive pulmonary disease, septic shock, atopic dermatitis, bronchitis, rheumatoid arthritis and osteoarthritis.

Since the recognition that cyclic AMP is an intracellular second messenger (E. W. Sutherland, and T. W. Rall, Pharmacol. Rev., 1960, 12, 265), inhibition of the phosphodiesterases has been a target for modulation and, accordingly, therapeutic intervention in a range of disease processes. More recently, distinct classes of PDE have been recognized (J. A. Beavo and D. H. Reifsnyder, TiPS, 1990, 11, 150), and their selective inhibition has led to improved drug therapy (C. D. Nicholson, R. A. Challiss and M. Shahid, TiPS, 1991, 12, 19). More particularly, it has been recognized that inhibition of PDEIV can lead to inhibition of inflammatory mediator release (M. W. Verghese et al., J. Mol. Cell Cardiol., 1989, 12 (Suppl. II), S 61) and airway smooth muscle relaxation (T. J. Torphy in Directions for New Anti-Asthma Drugs, eds S. R. O'Donnell and C. G. A. Persson, 1988, 37, Birkhauser-Verlag). Thus, compounds that inhibit PDEIV, but which have poor activity against other PDE types, would inhibit the release of inflammatory mediators and relax airway smooth muscle without causing cardiovascular effects or antiplatelet effects.

Certain isoxazoline phosphonic acid compounds are disclosed to be useful for the treatment of diseases of the immune system in U.S. Pat. No. 5,006,515.

Certain catechol diethers are disclosed to be useful as PDEIV inhibitors and as such are useful in the treatment of inflammatory diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis and dermatitis, in copending U.S. patent application, Ser. No. 07/984,408 filed Dec. 2, 1992, which application is assigned to the assignee hereof.

Certain pyrimidone compounds have been disclosed to be useful as antidepressants by Saccomano et al., in European Patent Application EPO 247 725 A2. The same pyrimidone compounds have been disclosed to be useful against asthma and certain skin disorders in International Patent Application No. PCT/US90/02162, published May 30, 1991 as International Publication Number WO 91/07178.

SUMMARY OF THE INVENTION

This invention is concerned with a series of 3-aryl-2-isoxazoline compounds and to the pharmaceutically acceptable salts of such compounds. These new compounds are selective inhibitors of PDEIV, and as such are useful in the treatment of inflammatory conditions, AIDS, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis and dermatitis in mammals, especially humans.

The compounds of the present invention are of the formula (I) ##STR1## the racemic, racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof wherein

Y1 and Y2 are independently selected from the group consisting of hydrogen, (C1 -C6)alkyl, optionally substituted phenylalkyl having 1 to 6 carbons in the alkyl portion, optionally substituted phenoxyalkyl having 1 to 6 carbons in the alkyl portion, (C3 -C7)cycloalkyl, fluoro, chloro, bromo, iodo, --OR1 and --OR2 ;

wherein the aromatic portion of the optionally substituted phenylalkyl, and the aromatic portion of the optionally substituted phenoxyalkyl are optionally independently substituted with (C1 -C4)alkyl, (C1 -C4)alkoxy, halogen or CF3 ;

R1 is alkyl having 1 to 3 carbons, fluoromethyl, difluoromethyl or trifluoromethyl;

R2 is (C1 -C3)alkyl, (C3 -C7)cycloalkyl, alkoxyalkyl having 3 to 7 carbons in the alkoxy portion and 2 to 4 carbons in the alkyl portion, optionally substituted phenoxyalkyl having 2 to 6 carbons in the alkyl portion, optionally substituted phenylalkyl having 1 to 6 carbons in the alkyl portion, bicycloalkyl having 6 to 9 carbons or optionally substituted indanyl;

wherein the aromatic portion of the optionally substituted phenylalkyl, the aromatic portion of the optionally substituted phenoxyalkyl and the optionally substituted indanyl are optionally independently substituted with (C1 -C4)alkyl, (C1 -C4)alkoxy, halogen or CF3 ;

R3 is hydrogen, (C1 -C3)alkyl, mono-hydroxyalkyl having 1 to 3 carbons or alkoxyalkyl having 1 to 3 carbons in the alkyl portion and 1 to 3 carbons in the alkoxy portion;

R4 is hydrogen, (C1 -C5)alkyl, --COOH, alkoxyalkyl having 1 to 3 carbons in the alkyl portion and 1 to 3 carbons in the alkoxy portion, N-alkylaminoalkyl having 1 to 3 carbons in the alkylamino portion and 1 to 3 carbons in the alkyl portion or N,N-dialkylaminoalkyl having a total of 2 to 6 carbons in the dialkylamino portion and 1 to 3 carbons in the alkyl portion;

or R3 and R4 are taken together with the carbon atoms to which they are attached and form --CH2 OCH2 OCH2 --; and

R5 is hydrogen, --CHO, amino, aminoalkyl having 1 to 3 carbons, ##STR2## mono-hydroxyalkyl having 1 to 3 carbons, --(CH2)b --COOR6, --COR7, --(CH2)m CO2 H, (C1 -C4)alkyl, hydroxy, --(CH2)q CONX2 X3, --(CH2)r SO2 NX4 X5, --(CH2)s PO3 H2 or ##STR3## wherein b is 0 or an integer from 1 to 6; m, n, q, r, s and t are independently 0, 1, 2, 3 or 4;

R6 and R7 are each independently (C1 -C4)alkyl;

X1 is hydrogen, (C1 -C4)alkyl, --O(C1 -C4)alkyl or alkoxyphenyl having one to four carbon atoms in the alkoxy portion;

X2, X3, X4 and X5 are each independently hydrogen or (C1 -C3)alkyl; and

X6 is (C1 -C3)alkyl or phenyl;

provided that when R1 is (C1 -C3)alkyl, R2 is (C1 -C3)alkyl, R3 is hydrogen, and R4 is hydrogen then R5 is not --(CH2)s PO3 H2 ; and

when R4 is --COOH then R5 is not --COOH; and that

both Y1 and Y2 cannot be hydrogen at the same time.

A preferred group of compounds or the pharmaceutically acceptable salts thereof of this invention are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring.

A more preferred group of compounds or the pharmaceutically acceptable salts thereof of this invention are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is (C3 -C7)cycloalkyl, bicycloalkyl having 6 to 9 carbons, or phenylalkyl having 1 to 6 carbons in the alkyl portion; R3 is hydrogen or (C1 -C3)alkyl; R4 is hydrogen or (C1 -C5)alkyl; and R5 is --(CH2)m CO2 H, --CHO, --COCH3, amino, hydroxy, mono-hydroxyalkyl having 1 to 3 carbons, aminoalkyl having 1 to 3 carbons, or ##STR4## wherein X1 is (C1 -C4)alkyl or alkoxyphenyl having one to four carbon atoms in the alkoxy portion and n is 0 or an integer from 1 to 3.

Another more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is 5-phenylpentyl; R3 is hydrogen; R4 is hydrogen or CH3 and R5 is --(CH2)s PO3 H2 wherein s is 0 or 1.

Further, another more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is cyclopentyl; R3 is hydrogen; R4 is hydrogen and R5 is --(CH2)s PO3 H2 wherein s is 0.

Furtherstill, another more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl, R2 is 4-phenylbutyl, 5-phenylpentyl or cyclopentyl, R3 is hydrogen or (C1 -C3)alkyl; R4 is hydrogen or (C1 -C5)alkyl; and R5 is --(CH2)m CO2 H,

--CHO, --COOH3, amino, hydroxy, mono-hydroxyalkyl having 1 to 3 carbons, aminoalkyl having 1 to 3 carbons, or ##STR5## wherein X1 is (C1 -C4)alkyl or alkoxyphenyl having one to four carbon atoms in the alkoxy portion and n is 0 or an integer from 1 to 3.

Yet another more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is 5-phenylpentyl; R3 is hydrogen or (C1 -C3)alkyl; R4 is hydrogen or (C1 -C5)alkyl and R5 is --(CH2)m CO2 H, --CHO, --COCH3, amino, hydroxy, mono-hydroxyalkyl having 1 to 3 carbons, aminoalkyl having 1 to 3 carbons, or ##STR6## wherein X1 is (C1 -C4)alkyl or alkoxyphenyl having one to four carbon atoms in the alkoxy portion and n is 0 or an integer from 1 to 3.

Yet still another more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is 5-phenylpentyl; R3 is hydrogen or (C1 -C3)alkyl; R4 is hydrogen or (C1 -C5)alkyl and R5 is --(CH2)m CO2 H, --CHO, --COCH3, hydroxy or mono-hydroxyalkyl having 1 to 3 carbons.

A most preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is 5-phenylpentyl; R3 is hydrogen or (C1 -C3)alkyl; R4 is hydrogen or (C1 -C5)alkyl and R5 is --(CH2)m CO2 H.

Yet still another most preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is 5-phenylpentyl; R3 is hydrogen; R4 is hydrogen or (C1 -C5)alkyl and R5 is --(CH2)m CO2 H wherein m=0.

A particularly preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y1 is --OR1 and is attached to the 4-position of the phenyl ring and Y2 is --OR2 and is attached to the 3-position of the phenyl ring, wherein R1 is methyl; R2 is 5-phenylpentyl; R3 is hydrogen; R4 is hydrogen, methyl, ethyl or propyl and R5 is --(CH2)m CO2 H wherein m=0.

Most particularly preferred compounds of this invention are (+) or (-)-5-ethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic acid. Of the two, (-)-5-ethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!-phenyl-2-isoxazoline-5-carboxylic acid is the more preferred compound.

The term alkyl encompasses both straight and branched chains. The aromatic portion of the optionally substituted phenylalkyl, the aromatic portion of the optionally substituted phenoxyalkyl and the optionally substituted indanyl may be substituted by one or more substituents.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention having the formula (I) are comprised of the racemic, racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof. The compounds of the present invention, having the formula I as defined above, are readily and generally prepared by the following reaction processes.

Compounds of the formula (I) wherein R5 is a carboxylic acid can be synthesized by mixing a methanol solution of the corresponding alkyl ester, wherein R5 is ethyl ester, with an aqueous solution of an inorganic base such as KOH. The mixture is stirred at room temperature until the reaction is substantially complete. The reaction mixture is worked-up according to methods well-known to those skilled in the art.

Compounds of the formula (I) wherein R5 is carboxymethyl (--CH2 CO2 H) are synthesized by reacting a compound of the formula (I) wherein R5 is hydroxymethyl (--CH2 OH) with p-toluenesulfonyl chloride in the presence of a tertiary amine such as triethylamine in an inert solvent at 0 C. to 50 C. to give a compound of the formula (I) wherein R5 is --CH2 OTs, which is reacted with lithium, sodium or potassium cyanide in an inert solvent such as DMSO at 0 C. to 100 C. to give a compound of the formula (I) wherein R5 is --CH2 CN, which is hydrolyzed with an inorganic base such as KOH in water and an alcoholic solvent at room temperature to 100 C.

The compounds of formula (I) wherein R5 is an aldehyde can be synthesized by dissolving the corresponding compound of formula (I) wherein R5 is --CONH-alkyl in a dry inert solvent such as tetrahydrofuran, decreasing the temperature of the solution to between -65 to -78 C. and then adding dropwise 3 to 5 equivalents of diisobutylaluminum hydride (DIBAL-H) in hexane. The reaction mixture is maintained at about -78 C. for about 30 to 60 minutes and then allowed to warm to room temperature. The reaction mixture is worked-up according to methods well known to those skilled in the art. The resulting aldehyde compound can be optionally reduced to obtain the corresponding alcohol. The aldehyde compound is dissolved in an alcoholic solvent and treated with sodium borohydride; the mixture is stirred at room temperature until the reaction is substantially complete.

Compounds of the formula (I) wherein R5 is hydroxy can be synthesized by dissolving the corresponding acyloxy derivative, such as when R5 is --OCOCH3, in an alcoholic solvent and treating the solution with approximately 1.1 equivalents of sodium methoxide. The reaction mixture is stirred at room temperature until the reaction is substantially complete, which is usually about 1 hour.

Compounds of the formula (I) wherein R5 is a mono-hydroxyalkyl, are synthesized by reducing the corresponding ester, wherein R5 is an alkyl ester, with diisobutylaluminum hydride (DIBAL-H) according to the following procedure. A compound of formula (I) wherein R5 is a methyl or ethyl ester, is dissolved in THF and chilled to about -78 C. Approximately 2 to 4 equivalents of DIBAL-H in hexane is added to the cold THF mixture. The solution is warmed to about -30 C. and then quenched with a dilute solution of HCl.

Alternatively, the compounds of formula (I) wherein R5 is hydroxymethyl, are synthesized by reducing a compound of formula (I) wherein R5 is an aldehyde. The aldehyde compound is dissolved in an alcoholic solvent and treated with sodium borohydride; the mixture is stirred at room temperature until the reaction is substantially complete. Further, the compounds of formula (I) wherein R5 is a 1-hydroxyalkyl (i.e., --CO(OH)alkyl) are synthesized by reducing a corresponding compound of formula (I) wherein R5 is a ketone moiety (i.e., --COalkyl) according to the following procedure. The ketone compound of formula (I) is dissolved in an alcoholic solvent and cooled to about 0 C., to which is added sodium borohydride. The mixture is stirred until the bubbling ceases and then stirred at room temperature for approximately 1 hour.

Certain compounds of the formula (I) are synthesized according to the following procedure. To a mixture of N-chlorosuccinimide and pyridine in an inert solvent, such as methylene chloride, is added an oxime of the formula ##STR7## wherein Y1 and Y2 are as defined above for formula (I). The mixture is allowed to stir for about 2 to 5 hours, preferably about 2 hours. A compound of the formula ##STR8## wherein R3, R4 and R5 are as defined above for formula I, is added followed by the addition of triethylamine to the mixture and the mixture stirred for about 2 hours more at room temperature. The reaction is worked up according to methods well known to those skilled in the art.

Compounds of the formula (I) wherein R5 is aminomethyl are synthesized according to the following procedure. A compound of the formula ##STR9## wherein Y1, Y2, R3 and R4 are as defined above for formula (I), is dissolved in a mixture of methanol and water. An inorganic base such as KOH is added to the mixture and the reaction mixture is allowed to stir at room temperature for about 12 to 24 hours, preferably 16 hours. The reaction is worked-up according to methods well-known to those skilled in the art.

Compounds of the formula (I) wherein R4 is --COOH and R5 is an amino group are synthesized according to the following procedure. A compound of the formula ##STR10## wherein Y1, Y2 and R3 are as defined above for formula (I), is reacted with bromotrimethylsilane for about 12 to 24 hours, preferably 16 hours. Acetonitrile is added, for solubility if necessary, to the reaction mixture and the mixture is heated to reflux until the reaction is substantially complete. The reaction is worked-up according to methods well-known to those skilled in the art.

Compounds of formula (I) wherein R5 is --(CH2)s PO3 H2 are synthesized according to the following procedure. A solution of the appropriate phosphonate dissolved in trimethylsilylbromide is stirred for about 2 hours at room temperature. The mixture is evaporated and the residue is diluted with H2 O and an organic solvent such as CH2 Cl2 and stirred for about 2 hours. The mixture is filtered and the aqueous layer is basified with an aqueous inorganic base such as 1N NaOH. The organic layer is discarded and the aqueous layer is washed with additional organic solvent such as CH2 Cl2. The aqueous layer is acidified and extracted with an organic solvent such as EtOAc. Evaporating the EtOAc yields the desired compound.

The synthetic methods outlined above together with the following examples describe methods which were and can be employed to prepare the compounds of this invention.

As ascertained by one skilled in the art enabled by this disclosure, pharmaceutically-acceptable acid addition salts of certain compounds of this invention include, but are not limited to, those formed with HCl, HBr, HNO3, H2 SO4, H3 PO4, CH3 SO3 H, p--CH3 C6 H4 SO3 H, CH3 CO2 H, gluconic acid, tartaric acid, maleic acid and succinic acid. In the case of those compounds of the formula (I) which contain a further basic nitrogen, it will, of course, be possible to form diacid addition salts (e.g., the dihydrochloride) as well as the usual monoacid addition salt. As ascertained by one skilled in the art enabled by this disclosure, pharmaceutically-acceptable cationic salts of certain compounds of this invention include, but are not limited to, those of sodium, potassium, calcium, magnesium, ammonium, N,N'-dibenzylethylenediamine, N-methylglucamine (meglumine), ethanolamine and diethanolamine.

The starting materials and reagents required for the synthesis of the compounds of the present invention are readily available, either commercially, according to literature methods, or by methods exemplified in Preparations below.

The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit PDEIV and, consequently, demonstrate their effectiveness for treating inflammatory diseases is shown by the following in vitro assay.

BIOLOGICAL ASSAY (Human Lung PDEIV)

Thirty to forty grams of human lung tissue is placed in 50 ml of pH 7.4 Tris/phenylmethylsulfonyl fluoride (PMSF)/sucrose buffer and homogenized using a Tekmar Tissumizer (Tekmar Co., 7143 Kemper Road, Cincinnati, Ohio 45249) at full speed for 30 seconds. The homogenate is centrifuged at 48,000g for 70 minutes at 4 C. The supernatant is filtered twice through a 0.22 μm filter and applied to a Mono-Q FPLC column (Pharmacia LKB Biotechnology, 800 Centennial Avenue, Piscataway, N.J. 08854) pre-equilibrated with pH 7.4 Tris/PMSF buffer. A flow rate of 1 ml/minute is used to apply the sample to the column, followed by a 2 ml/minute flow rate for subsequent washing and elution. Sample is eluted using an increasing, step-wise NaCl gradient in the Ph 7.4 Tris/PMSF buffer. Eight ml fractions are collected. Fractions are assayed for specific PDEIV activity, determined by 3 H!cAMP hydrolysis and the ability of a known PDEIV inhibitor (e.g. rolipram) to inhibit that hydrolysis. Appropriate fractions are pooled, diluted with ethylene glycol (2 ml ethylene glycol/5 ml of enzyme prep) and stored at -20 C. until use.

Compounds are dissolved in DMSO at a concentration of 10 mM and diluted 1:25 in water (400 μM compound, 4% DMSO). Further serial dilutions are made in 4% DMSO to achieve desired concentrations. Final DMSO concentration in the assay tube is 1%. In duplicate the following are added, in order, to a 1275 mm glass tube (all concentrations are given as final concentrations in assay tube).

i) 25 μl compound or DMSO (1%, for control and blank)

ii) 25 μl pH 7.5 Tris buffer

iii) 3 H!cAMP (1 μM)

iv) 25 μl PDEIV enzyme (for blank, enzyme is preincubated in boiling water for 5 minutes)

The reaction tubes are shaken and placed in a water bath (37 C.) for 20 minutes, at which time the reaction is stopped by placing the tubes in a boiling water bath for 4 minutes. Washing buffer (0.5 ml, 0.1M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)/0.1M NaCl, pH 8.5) is added to each tube on an ice bath. The contents of each tube are applied to an Affi-Gel 601 column (Biorad Laboratories, P.O. Box 1229, 85A Marcus Drive, Melville, N.Y. 11747) (boronate affinity gel, 1 ml bed volume) previously equilibrated with washing buffer. 3 H!cAMP is washed with 26 ml washing buffer, and 3 H!5'AMP is then eluted with 4 ml of 0.25M acetic acid. After vortexing, 1 ml of the elution is added to 3 ml of scintillation fluid in a suitable vial, vortexed and counted for 3 H!.

% Inhibition is determined by the formula: ##EQU1## IC50 is defined as that concentration of compound which inhibits 50% of specific hydrolysis of 3 H!cAMP to 3 H!5'AMP.

For administration to humans to inhibit PDEIV in the treatment of inflammatory conditions, AIDS, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases, oral dosages of the compounds are generally in the range of from 0.1-500 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 0.1 to 50 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Tablets or capsules can be given in multiple dosages to meet the dosage requirement. Dosages for intravenous administration are typically within the range of 0.1 to 10 mg per single dose as required. For intranasal or inhaler administration, the dosage is generally formulated as a 0.1 to 1% (w/v) solution. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and all such dosages are within the scope of this invention.

For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in an admixture with a pharmaceutical diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovales either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. They may be injected parenterally; for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances; for example, enough salts or glucose to make the solution isotonic. For topical administration, they are best used in the form of solutions, lotions, ointments, salves and the like.

Thus in a further aspect the invention provides pharmaceutical compositions comprising a compound of the formula (I), or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable diluent or carrier.

This invention provides a method of inhibiting PDEIV in a mammal in need thereof which method comprises administering to said mammal an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

This invention further provides a method of treating an inflammatory condition in a mammal in need thereof which comprises administering to said mammal an antiinflammatory amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

Further still, this invention provides a method of treating AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis or shock in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof.

The present invention is illustrated by the following examples, but it is not limited to the details thereof.

EXAMPLE 1 3- 4-Methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic Acid

To a mixture of 1.00 g (2.43 mmol) of the compound of Preparation 15, 15 ml of MeOH, and 5 ml of water was added 273 mg (4.86 mmol) of KOH. The mixture was stirred overnight at RT and was then partially evaporated to remove MeOH. The residue was diluted with water to a volume of 125 ml, acidified with 6N HCl solution, and extracted with EtOAc (2125 ml). The combined extracts were dried (Na2 SO4) and evaporated to give 729 mg (78%) of the title compound as an oil. 1 H NMR (CDCl3): δ 1.44-1.94 (6H, m), 2.64 (2H, t), 3.66-3.70 (2H, m), 3.89 (3H, s), 4.02 (2H, q, J=7), 5.18 (1H, t, J=10), 6.83 (1H, d, J=8), 7.02 (1H, dd, J=8, 2), 7.11-7.31 (6 H, m). FABMS (m/e): 384 (M+ +1).

EXAMPLES 2-5

The following compounds were prepared substantially according to the procedure of Example 1.

__________________________________________________________________________ ##STR11##ExampleEster  R4          R3             M.P. C.                  Data__________________________________________________________________________2    Compound of       Me H  101-103                  1 H NMR(CDCl3): δ 1.40-1.88(6H,Preparation 16    m), 1.72(3H, s), 2.58(2H, t, J=7),                  3.23(1H, d, J=16), 3.78(1H, d,                  J=16), 3.93(3H, s), 3.96(2H, q,                  J=7), 6.76(1H, d, J=8), 6.93(1H,                  dd, J=8, 2), 7.06-7.22(6H, m)3    Compound of       H  Mea             101-104                  1 H NMR(CDCl3): δ 1.41(3H, d,Preparation 17    J=7), 1.40-1.88(6H, m), 3.94(3H,                  s), 3.96-4.01(1H, m), 3.99(2H, q,                  J=7), 5.00-5.07(1H, m), 6.78(1H,                  d, J=8), 7.04(1H, d, J=8), 7.10-                  7.24(6H, m), 7.34(1H, s).                  FABMS (m/e): 398(M+  + 1)4    Compound of       Et H   138-140b                  Anal. Calc'd for C24 H29 NO5 : C,Preparation 18    70.05; H, 7.10; N, 3.40. Found:                  C, 70.11; H, 7.21; N, 3.425    Compound of       Pr H  153-155                  Anal. Calc'd for C25 H31 NO5 : C,Preparation 19    70.56; H, 7.34; N, 3.29. Found:                  C, 70.49; H, 7.39; N, 3.33__________________________________________________________________________ a trans stereochemistry b recrystallized from EtOAc
EXAMPLE 6 (+)-5-Ethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic Acid

A mixture of 1.03 g (2.5 mmol) of the compound of Example 4 and 303 mg (2.5 mmol) of (R)-(+)-α-methylbenzylamine were dissolved in 50 ml of MeOH and the solvent was removed. The residual oil crystallized on standing in the refrigerator overnight and was triturated in ether. The solid, 1.17 g, was recrystallized four times from EtOAc to give 340 mg of a fluffy white solid, mp 144-145 C.; α!D +26.3 (MeOH). The salt was partitioned between 20 ml of aqueous 1N HCl solution and 40 ml of EtOAc. The organic layer was washed with additional aqueous 1N HCl solution (220 ml), dried (MgSO4), and evaporated to 234 mg of a solid. Recrystallization from hexane-EtOAc provided 192 mg of the title compound, mp 122-124, α!D +30.7 (CHCl3). Calc'd. for C24 H29 NO5 : C, 70.05; H, 7.10; N. 3.48. Found: C, 70.12; H, 6.80; N, 3.32.

EXAMPLE 7 (-)-5-Ethyl-3- 4-methoxy-3-(phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic Acid

All the mother liquors derived from the (R)-α-methylbenzylamine salt described in Example 6 were combined, concentrated, and partitioned between EtOAc (100 ml) and aqueous 1N HCl solution (50 ml). The organic layer was separated, washed with additional aqueous 1N HCl solution (250 ml), dried (MgSO4), and evaporated to 722 mg (1.75 mmol) of a solid. The solid and 212 mg (1.75 mmol) of (S)-(-)-α-methylbenzylamine were dissolved in 30 ml of EtOAc and crystallization was induced by scratching with a glass rod to yield 605 mg of salt. Two recrystallizations from EtOAc gave 483 mg of pure salt, mp 145-146 C.; α!D -26.3 (MeOH). The salt was neutralized as described in Example 6 to provide 334 mg of the title compound, mp 122-123 C. α!D -31.0 (CHCl3). Calc'd. for C24 H29 NO5 : C, 70.05; H 7.10; N, 3.48. Found: C, 70.02; H, 6.85; N, 3.36.

EXAMPLE 8 (-)-3- 4-Methoxy-3-(5-phenylpentyloxy)!phenyl-5-methyl-2-isoxazoline-5-carboxaldehyde

To a solution of 290 mg (0.579 mmol) of the compound of Preparation 22 in 20 ml of dry THF at about -78 C. was added dropwise 1.74 ml (1.74 mmol) of a solution of 1M diisobutylaluminum hydride in hexane at such a rate that the reaction temperature was maintained below about -65 C. After about 20 min of stirring the reaction was allowed to warm to RT where TLC analysis indicated the presence of starting material. The mixture was recooled to about -78 C., treated with an additional 0.580 ml of 1M diisobutylaluminum hydride solution, and then allowed to warm to RT. A solution (6 ml) of 1N aqueous HCl was added and the organic layer was extracted with EtOAc (250 ml). The combined extracts were dried (MgSO4) and evaporated to 246 mg of a yellow oil. Purification by flash chromatography using a EtOAc-hexane (1:1) eluant gave 137 mg of the title compound as an oil. 1 H NMR (CDCl3): δ1.28-1.93 (6H, m), 1.58 (3H, s), 2.63 (2H, t, J=7), 3.06 (1H, d, J=16), 3.66 (1H, d, J=16), 3.90 (3H, s), 4.03 (2H, t, J=7), 6.83 (1H, d, J=8), 7.00 (1H, d, J=8), 7.15-7.31 (6H, m) 9.65 (1H, s); MS (m/e): 382 (M+ +1), 352; α!D -35.1 (CHCl3).

EXAMPLES 9-11

The following compounds were prepared substantially according to the procedure of Example 8 substituting the indicated amide for that of Procedure 22.

__________________________________________________________________________ ##STR12##ExampleAmide     R4        M.P. C.              α!D (CHCl3)                    Data__________________________________________________________________________9    Cmpd of     Me oil  +36.6                    MS(m/e): 382(M+  + 1), 352Prep. 2410   Cmpd of     Pr oil  -29.4                    1 H NMR(CDCl3): δ 0.96(3H,Prep. 28            t), 1.39-1.93(10H, m), 2.62                    (2H, t, J=8), 3.06(1H, d,                    J=17), 3.59(1H, d, J=17),                    3.86(3H, s), 4.00(3H, t, J=7),                    6.83(1H, d, J=8), 7.07(1H,                    dd, J=8, 2), 7.23-7.30(6H, m),                    9.67(1H, s)11   Cmpd of     Pr oil  +37.1                    MS(m/e): 410(M+  + 1), 382Prep. 27__________________________________________________________________________
EXAMPLE 12 5-Hydroxy-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline

To a solution of 500 mg (1.26 mmol) of the compound of Preparation 29 in 15 ml of MeOH was added 0.50 ml (1.50 mmol) of 3M NaOMe solution in MeOH. After stirring for about 1 hr at RT, the mixture was evaporated and the residue was diluted with 10 ml of ice water. The mixture was acidified with aqueous 6M HCl solution, extracted with EtOAc (250 ml), washed with brine (50 ml), dried (Na2 SO4), and evaporated to 307 mg of an oil. Purification by flash chromatography using a EtOAc-hexane (1:1) eluant afforded 307 mg of the title compound, mp 89-91 C. Anal. Calc'd. for C20 H25 NO4 : C, 70.96; H, 7.09; N, 3.93. Found: C, 70.86; H, 7.10; N, 3.97.

EXAMPLE 13 (+)-5-Hydroxymethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline

To a solution of 300 mg (0.617) of the compound of Preparation 20 in 10 ml of dry THF chilled to about -78 C. was added dropwise 1.85 ml (1.85 mmol) of 1M diisobutylaluminum hydride solution in hexane. After stirring for 20 min at about -78 C., the mixture was allowed to warm to about -20 C. and was quenched with 4 ml of aqueous 1N HCl solution. The mixture was concentrated, dissolved in 30 ml of EtOAc, washed with water (230 ml), dried (MgSO4), and evaporated to 200 mg of a brown oil.

A solution of 184 mg of the oil above in 3 ml of MeOH was treated with 19 mg (0.50 mmol) of sodium borohydride, and the mixture was allowed to stir at RT for about 16 h. The mixture was quenched with aqueous 1N HCl solution and was partially evaporated to remove MeOH. The residue was extracted with EtOAc (150 ml) and the organic layer was separated, washed with water, dried (MgSO4), and evaporated to a brown oil. Purification by flash chromatography (10 g of silica gel) using a EtOAc-hexane (2:3) eluant afford 96 mg of the title compound as an oil. 1 H NMR (CDCl3): δ 1.46-1.92 (6H, m), 2.62 (3H, t, J=8), 3.18-3.39 (2H, m), 3.63-3.90 (2H, m), 3.86 (3H, s), 4.80-4.85 (1H, m), 6.83 (1H, d, J=8), 7.02 (1H, dd, J=8, 2), 7.12-7.33 (6H, m), MS (m/e): 370 (M+ +1). α!D +58.0 (CHCl3).

EXAMPLE 14 (-)-5-Hydroxymethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline

The title compound was prepared substantially according to the procedure of Example 13 substituting the compound of Preparation 21 for the compound of Preparation 20. α!D -60.0 (CHCl3).

EXAMPLE 15 (+)-5-Hydroxymethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-5-methyl-2-isoxazoline

A solution of 200 mg (0.524 mmol) of the compound of Example 9 in 4 ml of MeOH was treated with 18 mg (0.524 mmol) of sodium borohydride and the mixture was stirred for about 16 h at RT. The mixture was quenched with aqueous 1N HCl solution and was partially evaporated to remove MeOH. The residue was diluted with 50 ml of water, extracted with EtOAc (250 ml), dried (MgSO4), and evaporated to 194 mg of an oil. Crystallization of the oil from hexane-ether (3:1) afforded 131 mg of the title compound, mp 76-78 C. α!D +34.7 (CHCl3). Anal. Calc'd for C23 H29 NO 4 1/4H2 O: C, 71.14; H, 7.60; N. 3.61. Found: C, 71.51; H, 7.72; N, 3.71.

EXAMPLE 16 (-)-5-Hydroxymethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-5-methyl-2-isoxazoline

The title compound was prepared substantially according to the procedure of Example 15 substituting the compound of Example 8 for the compound of Example 9, mp 86-88 C. α!D -38.2 (CHCl3). Anal. Calc'd. for C23 H29 NO4 1/4H2 O: C, 71.14; H, 7.60; N. 3.61. Found: C, 71.51; H, 7.72; N, 3.71.

EXAMPLE 17 (+/-)-5-Hydroxymethyl-3- 4-methoxy-3-(5-phenylpenytyloxy)!phenyl-5-methyl-2-isoxazoline

To a solution of 200 mg (0.47 mmol) of the compound of Preparation 16 in 5 ml of THF chilled to about -78 C. was added dropwise 1.03 ml (1.03 mmol) of 1.0M diisobutylaluminum hydride solution in hexane. The mixture was allowed to warm to about 0 C. where TLC analysis indicated the presence of starting material. After rechilling to about -78 C., an additional 1.03 ml of a 1.0M diisobutylaluminum hydride solution in hexane was added and the mixture was allowed to warm to about -30 C. The mixture was quenched with aqueous 1N HCl solution and after warming to RT was extracted with EtOAc (225 ml). The combined organic layers were dried (MgSO4) and evaporated to 199 mg of a yellow oil. Purification of the oil by flash chromatography (15 g of silica gel) using a EtOAc-hexane eluant (3:2) afforded 163 mg of an oil which spontaneously crystallized upon standing. Trituration with hexane-ether (3:1) afforded 69 mg of the title compound, mp 67-69 C. 1 H NMR (CDCl3): δ1.39 (3H, s), 1.41-1.94 (6H, m), 2.61 (2H, t, J=8), 2.96 (1H, d, J=16), 3.44 (1H, d, J=16), 3.49-3.72(2H, m), 3.85 (3H, s), 4.00 (2H, t, J=7), 6.82 (1H, d, J=9), 6.99 (1H, dd, J=2, 9), 7.14-7.32 (6H, m). FABMS (m/e): 384 (M+ +1).

EXAMPLE 18 (+)-5-Ethyl -5-hydroxymethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline

The title compound was prepared as an oil substantially according to the procedure of Example 13 substituting the compound of Preparation 25 for the compound of Preparation 20. 1 H NMR (CDCl3): δ 0.98 (3H, t, J=7), 1.52-1.93 (8H, m), 2.35-2.70 (1H, bd s), 2.65 (2H, t, J=7), 3.06 (1H, d, J=17), 3.36 (1H, d, J=17), 3.60 (1H, d, J=12), 3.75 (1H, d, J=12), 3.89 (3H, s), 4.04 (2H, t, J=7), 6.85 (1H, d, J=8), 7.04 (1H, dd, J=2, 8), 7.18-7.35 (6H, m). MS (m/e): 397, 362, 310, 91 (base). α!D +20.1 (CHCl3).

EXAMPLE 19 (-)-5-Ethyl-5-hydroxymethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline

The title compound was prepared as an oil substantially according to the procedure of Example 13 substituting the compound of Preparation 26 for the compound of Preparation 20. α!D -16.3 (CHCl3).

EXAMPLES 20-21

The following compounds were prepared as oils substantially according to the procedure of Example 15 substituting the indicated aldehyde for the compound of Example 9.

______________________________________ ##STR13##Ex.  Aldehyde  α!D (CHCl3)                     1 H NMR(CDCl3):______________________________________20   Cmpd of  +8.9                     δ 0.93(3H, t, J=7), 1.36-1.90Ex. 11               (10H, m), 2.62(2H, t, J=8),                     3.03(1H, d, J=17), 3.34(1H,                     d, J=17), 3.52-3.74(2H, m),                     3.86(3H, s), 4.01(2H, t, J=7),                     6.82(1H, d, J=8), 7.01(1H,                     dd, J=2, 8), 7.15-7.32(6H, m)21   Cmpd of  -9.8                     MS(m/e): 412(M+  + 1), 382,Ex 10                312______________________________________
EXAMPLES 22-28

The following compounds were prepared substantially according to the procedure of Preparation 15 substituting the indicated olefin for ethyl acrylate.

__________________________________________________________________________ ##STR14##Ex  R5    R4         R3               Olefin    M.P. C.                              Data__________________________________________________________________________22  H      H    H     CH2CH 2                         103-105                              Anal. Calc'd. for                              C21 H25 NO3.1/4H2                              O:                              C, 73.33; H, 7.32; N,                              4.07. Found: C,                              73.56; H, 7.20; N, 4.1323  Me     Me   H     Me2 CCH2                         83-85                              Anal. Calc'd. for                              C23 H29 NO3.1/4H2                              O:                              C, 74.26; H, 7.85; N,                              3.36. Found: C,                              74.56; H, 7.90; N, 3.8424  COCH3    H    H     CH2CHCOCH 3                         oil  1 H NMR(CDCl3): δ                              1.46-1.90(6H, m),                              2.35(3H, s), 2.62(2H,                              t, J=8), 3.39-3.62(2H,                              m), 3.86(3H, s), 4.01                              (2H, t, J=7), 4.97(1H,                              dd, J=6, 11), 6.83                              (1H, d, J=8), 7.03                              (1H, dd, J=2, 8), 7.15-                              7.33(6H, m)25  CONH2    H    H     CH2CHCONH 2                         152-154                              Anal. Calc'd for                              C22 H26 N2 O4 : C,                              69.08;                              H, 6.85; N, 7.32.                              Found: C, 68.80; H,                              6.64; N, 7.2626  (CH2)2 OH    H    H     CH2CH(CH2)2 OH                         84-86                              1 H NMR(CDCl3): δ                              1.40-1.81(8H, m),                              2.59(2H, t, J=7), 3.05                              (1H, dd, J=8, 17),                              3.43(1H, dd, J=10,                              17), 3.52(2H, q, J=5),                              3.77(3H, s), 3.96(2H,                              t, J=6), 4.56(1H, t,                              J=5), 4.70-4.75(1H,                              m), 6.98(1H, d, J=8),                              7.12-7.29(7H, m), MS                              (m/e): 384(M+  + 1)27  H      CH2 OCH2 OCH2 a                ##STR15##                         122-125                              1 H NMR(CDCl3): δ                              1.48-1.89(6H, m), 2.62(2H, t, J=8),                              3.86 (3H, s), 3.91-4.40(8H, m),                              4.69(1H, d, J=6), 4.87(1H, d, J=6),                              6.86(1H, d, J=8), 7.03(1H, dd, J=2,                              8), 7.17-7.32(6H, m), MS (m/e):                              412(M+  + 1)28  CH2 NHCOCF3    H    H     Preparation 14                         91-94                              1 H NMR(CDCl3): δ                              1.39-1.94(6H, m),                              2.56(2H, t, J=7), 2.95                              (1H, dd, J=8, 16) 3.17                              (1H, dd, J=12, 16),                              3.17-3.48(1H, m),                              3.60-3.68(1H, m),                              3.91(3H, s), 3.95(2H,                              t, J=7), 4.72-4.82(1H,                              m), 6.64(1H, bd s),                              6.75(1H, d, J=8),                              6.92(1H, dd, J=2, 8)                              7.07-7.22(6H, m).                              FABMS(m/e): 465                              (M+  + 1)__________________________________________________________________________ a cis stereochemistry in the ring juncture
EXAMPLE 29 5-Aminomethyl-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline Hydrochloride

A mixture of 250 mg (0.538 mmol) of the compound of Example 28, 5 ml of MeOH, and 1 ml of water was treated with 91 mg (1.62 mmol) of KOH and was allowed to stir for about 16 h at RT. The mixture was partially evaporated to remove MeOH and the residue was diluted with EtOAc (50 ml) and sat'd. aqueous NaHCO3 solution (50 ml). The organic layer was separated and washed with an additional 50 ml of sat'd. aqueous NaHCO3 solution, dried (MgSO4), and evaporated to an oil. NMR analysis indicated the presence of a small amount of starting material, so the oil was treated again as described above using 30 mg of KOH. After work-up 126 mg of an oil was obtained, which was treated with HCl gas in 3 ml of CHCl3. The solvent was evaporated and the semi-solid residue was triturated in ether to yield 70 mg of the title compound, mp 106-109 C. Anal. Calc'd for C22 H28 N2 O3 HCl: C, 63.78; H, 7.00; N, 6.76. Found: C, 63.93; H, 7.29; N, 6.65.

EXAMPLE 30 5-Amino-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic Acid Hydrobromide

A mixture of 50 mg (0.094 mmol) of the compound of Preparation 30 and 2 ml of bromotrimethylsilane was stirred for about 16 hr at RT. A precipitate was observed and a small amount of acetonitrile was added and the mixture was heated to reflux. The mixture was evaporated and the residue was triturated with ether to afford 57 mg of the title compound, mp 123-127 C. 1 H NMR (CD3 OD): δ 1.47-1.88 (6H, m), 2.64 (2 H, t, J=7), 3.82 (1H, d, J=17), 3.88 (3H, s), 4.02 (2H, t, J=8), 4.29 (1 H, d, J=17), 7.03 (1H, d, J=8), 7.12-7.33 (7H, m). FABMS (m/e): 477, 399.

EXAMPLES 31-32 Racemic Diastereomers of 5-(1-Hydroxyethyl)-3- 4-methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline

To a solution of 360 mg (0.944 mmol of the compound of Example 24 in 4 ml of MeOH chilled to about 0 C. was added 36.0 mg (0.944 mmol of NaBH4. After the bubbling ceased, the ice bath was removed and stirring was continued for about 1 h. Excess aqueous 1N HCl solution was added and the mixture was partially evaporated to remove MeOH. The residue was diluted with 50 ml of water and extracted with EtOAc (250 ml). The combined EtOAc extracts were dried (MgSO4) and evaporated to 360 mg of an oil, which was separated by flash chromatography (50 g of silica gel) using ether-hexane (7:3) and ether as eluants. The fractions containing the less polar diastereomer (Rf 0.28, ether) were combined and evaporated to 31 mg of an oil which was crystallized from hexane, mp 102-103 C. Anal. Calc'd for C23 H29 NO4 : C, 72.04; H, 7.62; N, 3.65. Found: C, 72.22; H, 7.57; N, 3.41.

The fractions containing the more polar diastereomer (Rf 0.23, ether) were combined and evaporated to 117 mg of an oil which was crystallized from hexane, mp 72-74 C. Anal. Calc'd for C23 H29 NO4 : C, 72.04; H, 7.62; N, 3.65. Found: C, 72.26; H, 7.57; N, 3.50.

EXAMPLES 33-36

The following compounds were prepared by saponification of the indicated ester, substantially according to the procedure of Example 1.

__________________________________________________________________________ ##STR16##Ex.   R2 R4         Ester              M.P. C.                    Data__________________________________________________________________________33 cyclopentyl      H  Cmpd. of              135-137                    Anal. Calc'd for C16 H19 NO5 :         Prep. 31   C, 62.94; H, 6.27; N, 4.59.                    Found: C, 62.82; H, 6.01; N,                    4.59.34 cyclopentyl      Me Cmpd. of              149-151                    Anal. Calc'd for         Prep. 32   C17 H21,NO5.1/4H2 O: C,                    62.99; H, 6.64; N, 4.32.                    Found: C, 63.22; H, 6.38; N,                    4.32.35 (CH2)4 Ph      H  Cmpd. of              108-110                    1 H NMR(DMSO-d6): δ 1.60-         Prep. 35   1.75(4H, m), 2.64(2H, t,                    J=6), 3.50-3.72(2H, m), 3.78                    (3H, s), 3.99(2H, t, J=6),                    5.11(1H, dd, J=3, 11), 6.99                    (1H, d, J=8), 7.16-7.30(7H,                    m).36    ##STR17##      H  Cmpd. of Prep. 33              oil   1 H NMR(CDCl3): δ 1.10-1.82 (8H,                    m), 2.28(1H, s), 2.49 (1H, d, J=2),                    3.65-3.70(2H, m), 3.85(3H, s), 4.20(1H, d, J=4),                    5.18(1H, dd, J=5, 12), 6.82(1H, d, J=8),                    7.01(1H, d, J=8), 7.27(1H, s).__________________________________________________________________________
EXAMPLE 37

3-(3-Cyclopentyloxy-4-methoxy)phenyl-2-isoxazoline-5-carboxaldehyde

To a solution of 250 mg (0.750 mmol) of the compound of Preparation 31 in 5 ml of THF chilled to about -78 C. was added dropwise 1.88 ml (1.88 mmol) of a 1M diisobutylaluminum hydride solution in hexane. The mixture was stirred for about 30 min at about -78 C. and was quenched by the addition of 3 ml of MeOH. Following the addition of 10 ml of 1N aqueous HCl solution, the mixture was allowed to warm to RT and was partially evaporated to remove THF and MeOH. The residue was extracted with EtOAc (250 ml) and the combined extracts were washed with sat'd. aqueous NaHCO3 (230 ml), dried (Na2 SO4), and evaporated to 205 mg of an oil. Purification of the oil by flash chromatography (50 g of silica gel) using an EtOAc-hexane (1:1 to 3:1) eluant afforded 173 mg of the title compound as an oil. The NMR spectrum indicated partial hydration of the aldehyde. 1 H NMR (CDCl3): δ 1.50-2.05 (8H, m), 3.20-3.62 (2.5H, m), 3.83 and 3.84 (3H, two s), 4.66-4.85 (1.5H, m), 4.98-5.07 (1H, m), 6.84 (1H, d, J=8), 7.04 (1H, dd, J=2, 8), 7.35 (1H, d, J=2), 9.80 (0.5H, s).

EXAMPLE 38 3- -3-(S)-(exo)-Bicyclo 2.2.1!hept-2-yloxy-4-methoxy!phenyl-5-methyl-2-isoxazoline-5 -carboxaldehyde

The title compound was prepared as an oil by diisobutylaluminum hydride reduction of the compound of Preparation 34, substantially according to the procedure of Example 8. 1 H NMR (CDCl3): δ 1.10-1.82 (8H, m), 1.56 (3H, s), 2.25-2.50 (1 H, m), 2.49 (1H, d, J=1), 3.06 (1H, d, J=17), 3.65 (1H, d, J=17), 3.84 (3H, s), 4.11 (1H, d, J=6), 6.81 (1H, d, J=6), 6.98 (1H, dd, J=2, 8), 7.27 (1H, d, J=2), 9.67 (1H, s). MS (m/e): 330 (M+ +1). α!D -24.3 (CHCl3).

EXAMPLES 39 and 40

The following compounds were prepared as oils by NaBH4 reduction of the indicated aldehydes, substantially according to the procedure of Example 15.

__________________________________________________________________________ ##STR18##Ex  R2 R4       Aldehyde              α!D (CHCl3)                    Data__________________________________________________________________________39  cyclopentyl     H Cmpd. of     1 H NMR(CDCl3): δ 1.50-2.05       Example 37   (8H, m), 3.15-3.36(2H, m),                    3.60-3.85(2H, m), 3.94(3H,                    s), 3.73-3.85(2H, m), 6.79                    (1H, d, J=8), 6.98(1H, dd,                    J=2, 8), 7.30(1H, d, J=2).                    FABMS(m/e): 292(M+  + 1)40   ##STR19##     Me       Cmpd. of Example 38             -4.8                    1 H NMR(CDCl3): δ 1.10-1.82 (m,                    8H), 1.39(3H, s), 1.97(1H, dd, J=5, 6),                    2.24-2.28(1H, m), 2.49(1H, d, J=4), 2.97(1H, d,                    J=17), 3.43(1H, d, J=17), 3.52-3.73(2H, m),                    3.84(3H, s), 4.21(1H, d, J=7), 6.81 (1H, d,                    J=8), 7.10(1H, dd, J=2, 8) 7.28(1H, d, J=2).                    FABMS(m/e): 332(M+  + 1)__________________________________________________________________________
EXAMPLE 41 3- 4-Methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazolin-5-ylphosphonic Acid

A solution of 50 mg of the compound of Preparation 38 in 1 ml of trimethylsilyl-bromide was stirred for about 2 h at RT. The mixture was evaporated and the residue was diluted with water (4 ml) and CH2 Cl2 (3 ml) and was stirred for about 2 h. The mixture was filtered and the aqueous layer was basified with aqueous 1N NaOH solution. The organic layer was separated and the aqueous layer was washed with additional CH2 Cl2 (215 ml). Acidification of the aqueous layer with aqueous 1N HCl solution, extraction with EtOAc (215 ml), drying (MgSO4), and evaporation afforded 42 mg of the title compound as an oil. 1 H NMR (DMSO-d6): d 1.37-1.78 (6H, m), 2.58 (2H, t, J=7), 3.57-3.77 (2H, m), 3.89 (3H, s), 3.96 (2H, t J=7), 4.61 (1H, t, J=10), 7.97 (1H, d, J=8), 7.08-7.26 (7H, m), FABMS (m/e): 420 (M+ +1).

EXAMPLES 42-45

The following compounds were prepared in an analogous manner to the procedure of Example 41 using as starting material the compounds from the indicated Preparations.

__________________________________________________________________________ ##STR20##          CmpdEx R2    R4       s  of Prep              M.P. C.                   Data__________________________________________________________________________42 (CH2)5 Ph    Me 0  39  175-177a                   Calc'd. for C22 H28 NO6 P.H2                   O: C,                   58.53; H, 6.65; N, 3.10. Found:                   C, 58.27; H, 6.61; N, 3.1643 (CH2)4 Ph    H  1  40  137-139                   Calc'd. for                   C22 H28 NO6 P.1/4H2 O: C,                   60.28;                   H, 6.51; N, 3.20. Found: C,                   60.17; H, 6.32; N, 3.1944 (CH2)5 Ph    Me 1  41  112-115a                   Calc'd. for C23 H30 NO6 P.H2                   O: C,                   59.29; H, 6.87; N, 3.00. Found:                   C, 58.99; H, 6.94; N, 2.9745 cyclopentyl    H  0  42  166-168                   1 H NMR(DMSO-d6): d 1.50-1.90                   (8H, m), 3.22-3.70(2H, m), 3.73                   (3H, s), 4.56(1H, t, J=12), 4.72-                   4.80(1H, m), 6.93(1H, d, J=8),                   7.09(1H, d, J=8), 7.16(1H, s)__________________________________________________________________________ a recrystallized from EtOAc
PREPARATION 1 4-Methoxy-3-(5-phenylpentyloxy)benzaldehyde Oxime

A mixture of 25.0 g (0.164 mol) of isovanillin, 26.9 g (0.164 mol) of 5-phenyl-1-pentanol, 64.5 g (0.246 mol) of triphenylphosphine and 250 ml of THF was treated dropwise with 42.8 g (0.246 mol) of diethyl azodicarboxylate. The mixture was heated to about 90 C. for about 6 h and then stirred overnight at RT. The solvent was evaporated and the residue was diluted with 500 ml of EtOAc, washed with water (1400 ml), 1N NaOH solution (2400 ml), brine (1400 ml), dried (MgSO4), and evaporated to 119 g of a brown oil. Purification by flash chromatography (750 g of silica gel) using an EtOAc-hexane (3:7) eluant afforded 29.8 g (61%) of the title compound as an oil. 1 H NMR (CDCl3): δ 1.42-1.92 (6H, m), 2.61 (2H, t, J=7), 3.91 (3H, s), 4.03 (2H, t, d=7), 6.91 (1H, d, J=8), 7.10-7.40 (m, 7H), 9.77 (s, 1H)

To a solution of 29.8 g (0.100 mol) of the aldehyde above in 300 ml of 95% ethanol was added 13.7 g (0.197 mol) of hydroxylamine hydrochloride in 100 ml of water followed by 16.6 g (0.197 mol) of sodium bicarbonate in small portions (gas evolution|). The mixture was stirred for about 4 h at RT and the ethanol was removed by evaporation. The residue was diluted with 250 ml of water and extracted with EtOAc (2200 ml). The combined extracts were dried (MgSO4) and evaporated to a yellow oil which was crystallized from hexane/ether to afford 15.0 g of the title compound, mp 65-67 C. 1 H NMR (CDCl3): δ 1.46-1.93 (6H, m), 2.62 (2H, t, J=7), 3.88 (3H, s), 4.02 (2H, t, J=7), 6.99-7.62 (m, 6H), 7.49 (1H, s), 8.04 (1H, s).

An additional 2.00 g of product was obtained as a second crop from the filtrate, mp 67-69 C. Evaporation of the filtrate and purification of the residue by flash chromatography using an EtOAc-hexane (2:3) eluant also provided an additional 4.18 g of product, mp 64-66 C.

PREPARATIONS 2-4

Reaction of the appropriate alcohol with isovanillin and condensation of the resulting aldehyde with hydroxylamine hydrochloride, substantially according to the procedure of Preparation 1, afforded the following compounds as oils.

______________________________________ ##STR21##Prep. # R2     1 H NMR CDCl3, δ______________________________________2     (CH2)4 Ph             1.70-1.90(m, 4H), 2.65(2H, t, J=7),             3.95(3H, s), 4.10(2H, t, J=7), 6.90(1H, d,             J=8), 6.94-7.26(6H, m), 6.97(1H, dd,             J=2, 8), 7.56(1H, s), 8.01(1H, s)3     cyclopentyl 1.50-2.02(8H, m), 3.94(3H, s),             4.62-4.80(1H, m), 6.91(1H, d, J=8),             6.97(1H, dd, J=8 and 1), 7.17(1H, d, J=1),             8.02(1H, s), 8.16(1H, s)  ##STR22##  1.10-1.80(8H, m), 2.26-2.32(1H, m), 2.47-2.52(1H, m),             3.84(3H, s), 4.21(1H, d, J=7), 6.82(1H, d, J=8),             6.98(1H, dd, J=8 and 2), 7.13(1H, d, J=2), 7.78(1H, s),             .03(1H, s)______________________________________
PREPARATION 5 Ethyl 2-Methylenebutyrate

A mixture of 5.0 g (0.019 mol) of triethyl 2-phosphonobutyrate, 5.5 g (0.039 mol) of K2 CO3, 6.2 g (0.076 mol) of 37% aqueous formaldehyde solution, and 15 ml of water was heated to about 80 C. for about 45 min. After cooling to RT, 75 ml of ether was added and the organic layer was separated, washed with brine (120 ml), dried (MgSO4), and filtered. The ether was carefully removed by distillation, leaving behind 2.1 g (87%) of the title compound as a clear oil which was used directly without further purification. 1 H NMR (CDCl3): δ 1.01 (3H, t, J=7), 1.24 (3H, t, J=7), 2.26 (2H, q, J=7) 4.14 (2H, q, J=7), 5.45 (1H, s), 6.06 (1H, s).

PREPARATION 6 Ethyl 2-Methylenepentanoate

Reaction of triethyl 2-phosphonopentanoate, substantially according to the procedure of Preparation 5, gave the title compound as an oil. 1 H NMR (CDCl3): δ 1.05 (3H, t, J=7), 1.28 (3H, t, J=7), 1.41-1.53 (2H, m), 2.87 (2H, q, J=7), 4.18 (2H, q, J=7), 5.49 (1H, s), 6.11 (1H, s).

PREPARATION 7 2-Methylenebutyric Acid

To a solution of 5.08 g (39.6 mmol) of the compound of Preparation 5 in 95 ml of EtOH and 40 ml of water was added 1.58 g (39.6 mmol) of solid NaOH, and the mixture was stirred for about 2 h at RT. An additional 0.15 g of NaOH was added and stirring was continued for about 2 h. The mixture was partially evaporated to remove the EtOH and the residue was diluted with 20 ml of H2 O and acidified to pH 2 with aqueous 6N HCl solution. Extraction with EtOAc, drying (MgSO4), and evaporation afforded 2.49 g (63%) of the title compound as an oil. 1 H NMR (CDCl3): δ 1.11 (3H, t, J=7), 2.34 (2H, q, J=7), 5.66 (1H, s), 6.30 (1H, s), 11.78 (1H, bd s).

PREPARATION 8 2-Methylenepentanoic Acid

Reaction of the compound of Preparation 6, substantially according to the procedure of Preparation 7, gave the title compound as an oil. 1 H NMR (CDCl3): δ 0.91 (3H, t, J=7), 2.40-2.54 (2H, m), 2.26 (2H, t, J=7), 5.62 (1H, s), 6.27 (1H, s).

PREPARATION 9 (S)-(-)-(N-α-Methylbenzyl)acrylamide

To a solution of 5.0 g (0.055 mol) of acryloyl chloride in 30 ml of CH2 Cl2 chilled to about 0 C. was added dropwise 7.1 ml (6.7 g, 0.055 mol) of (S)-(-)-α-methylbenzylamine. After the exotherm had subsided, 8.5 ml (6.2 g, 0.061 mol) of triethylamine was added dropwise and the mixture was allowed to warm to RT. Following about 2 h of additional stirring, the solvent was removed by evaporation and the residue was taken up in 200 ml of EtOAc and washed with aqueous 1N HCl solution, aqueous sat'd. NaHCO3 solution, dried (MgSO4), and evaporated to a solid. Trituration in hexane-ether afforded 7.8 g of the title compound as a solid, mp 97-99 C. 1 H NMR (CDCl3): δ 1.50 (3H, d, J=7), 5.11-5.21 (1H, m), 5.63 (1H, dd, J=2, 10), 5.77 (1H, bd s), 6.06 (1H, dd, J=10, 13), 6.26 (1H, dd, J=1, 17), 7.19-7.32 (5H, m).

PREPARATION 10 (S)-(-)-(N-α-Methylbenzyl)-2-methylpropionamide

To a solution of 5.00 g (0.0581 mol) of methacrylic acid in 100 ml of THF was added 7.03 g (0.0581 mol) of (S)-(-)-α-methylbenzylamine, 7.84 g (0.0581 mol) of hydroxybenztriazole, and 11.1 g (0.0581 mol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After stirring for about 4 h at RT, the solvent was removed by evaporation and the residue was taken up in 200 ml of BOAc and washed with water (2100 ml), aqueous 1N HCl solution (2100 ml), sat'd. aqueous NaHCO3 solution, dried (MgSO4), and evaporated to solid. Trituration in hexane-ether (2:1) afforded 8.68 g of the title compound as a white solid, mp 95-98 C. 1 H NMR (CDCl3): δ 1.51 (3H, d, J=7), 1.93 (3H, s), 5.09-5.19 (1H, m), 5.29 (1H, s), 5.65 (1H, s), 5.95 (1H, bd s), 7.20-7.34 (5H, m).

PREPARATIONS 11-13

Reaction of the appropriate acid with (R)-(+)-α-methylbenzylamine, substantially according to the procedure of Preparation 10, afforded the following compounds.

__________________________________________________________________________ ##STR23##Prep. #Q  Acid  M.P. C.              1 H NMR CDCl3, δ__________________________________________________________________________11   Me Methacryclic         93-95              1.53(3H, d, J=7), 1.97(3H, s), 5.10-5.23   acid       (1H, m), 5.23(1H, s), 5.64(1H, s), 6.01(1H,              bd s), 7.25-7.37(5H, m)12   Et Cmpd of         oil  1.07(3H, t, J=7), 1.53(3H, d, J=7), 2.34   Prep 7     (2H, q, J=7), 5.13-5.25(1H, m), 5.26(1H,              s), 5.59(1H, s), 6.06(1H, bd s), 7.20-7.35              (5H, m)13   Pr Cmpd of         69-71              0.91(3H, t, J=7), 1.29-1.54(2H, m), 1.53   Prep 8     (3H, d, J=8), 2.28(2H, t, J=8), 5.12-5.22              1H, m), 5.24(1H, s), 5.57(1H, s), 5.96(1H,              bd s), 7.25-7.36(5H, m)__________________________________________________________________________
PREPARATION 14 (N-Trifluoroacetyl)allylamine

A solution of 9.97 g (0.175 mol) of allylamine in 100 ml of pyridine chilled to about 0 C. was treated dropwise with 37.2 g (0.175 mol) of trifluoroacetic anhydride. After about 2 h of stirring the solvent was removed by evaporation. The residue was taken up in 200 ml of CH2 Cl2 and washed with aqueous 1N HCl solution (2100 ml), sat'd. aqueous NaHCO3 solution, dried (Na2 SO4), and evaporated to give 18.9 g (79%) of the title compound as an oil. 1 H NMR (CDCl3): d 3.97 (2H, t, J=5), 5.20 (1H, s), 5.27 (1H, d, J=10), 5.74-5.88 (1H, m), 6.57 (1H, bd s).

PREPARATION 15 3- 4-Methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazoline-5-carboxylic Acid Ethyl Ester

To a mixture of 1.28 g (9.57 mmol) of N-chlorosuccinimide, 200 μl of pyridine, and 200 ml of CH2 Cl2 was added 2.00 g (6.38 mmol) of the compound of Preparation 1 in a solution of 15 ml of CH2 Cl2. An exotherm was observed after about 10 min and following about 2 h of stirring at RT, 644 mg (698 μl, 6.38 mmol) of ethyl acrylate was added followed by 966 mg (1.33 ml, 9.57 mmol) of triethylamine. After the exotherm subsided, the mixture was stirred for about 2 h at RT. The mixture was diluted with 250 ml of CH2 Cl2 and washed with aqueous 1N HCl solution, sat'd. aqueous NaHCO3 solution, dried (Na2 SO4), and evaporated to an oil. Purification by flash chromatography (100 g of a silica gel) using an EtOAc-hexane (2:3) eluant afforded 1.82 g (69%) of the title compound as an oil. 1 H NMR (CDCl3): δ 1.29 (3H, t, J=7), 1.40-1.91 (6H, m), 2.60 (2H, t, J=7), 3.55-3.58 (2H, m), 3.95 (3H, s), 3.99 (2H, t, J=7) 4.22 (2H, q, J=7), 5.05-5.12 (1H, m), 6.79 (1H, d, J=8), 6.95-7.31 (7H, m).

PREPARATIONS 16-30

The following compounds were prepared substantially according to the procedure in Preparation 15 substituting the indicated olefin for ethyl acrylate.

__________________________________________________________________________ ##STR24##Prep #    R5     R4               R3                  Olefin M.P. C.                              Data__________________________________________________________________________16  CO2 Et Me  H  Ethyl  oil  1 H NMR (CDCl3): δ                              1.25(3H, t, J=7), 1.37-1.90(6H, m),                              1.64                  α-methacrylate                              (3H, s), 2.54(2H, t, J=7), 3.11(1H, d,                              J=15), 3.77(1H, d, J=15),                              3.83(3H, s), 3.95(2H, q, J=7),                              4.17(2H, q, J=7), 6.75(1H, d, J=8),                              6.90-8.28(7H, m)17  CO2 Et H   Mea                  Ethyl  oil  MS(m/e): 425(M+), 279, 91(base)                  crotonate18  CO2 Et Et  H  Cmpd of                         oil  MS(m/e): 439(M+), 310, 105                  Prep 519  CO2 Et Pr  H  Cmpd of                         oil  FABMS(m/e): 454(M+), 380, 310                  Prep 620  (S)CONHCH(Me)Phb           H   H  Cmpd of                         85-90                              Anal. Calc'd for C30 H34                              N2 O4 : C, 74.05; H, 7.04;                              N, 5.76.                  Prep 9      Found: C, 74.16; H, 6.93; N, 5.88.21  (S)CONHCH(Me)Phc           H   H  Cmpd of                         91-101                              Anal. Calc'd for C30 H34                              N2 O4 : C, 74.05; H, 7.04;                              N, 5.76.                  Prep 9      Found: C, 74.32; H, 6.94; N, 5.71.22  (S)CONHCH(Me)Phd           Me  H  Cmpd of                         113-116                              Anal. Calc'd for C31 H36                              N2 O4 : C, 74.37; H, 7.25;                              N, 5.60.                  Prep 10     Found: C, 74.17; H, 6.87; N, 5.5323  (R)CONHCH(Me)Phe           Me  H  Cmpd of                         97-99                              Anal. Calc'd for C31 H36                              N2 O4.1/4 H2 O: C,                              73.64; H, 7.23; N, 5.55.                  Prep 11     Found: C, 73.83; H, 7.35; N, 5.6024  (R)CONHCH(Me)Phf           Me  H  Cmpd of                         111-113                              Anal. Calc'd for C31 H36                              N2 O4 : C, 74.37; H, 7.25;                              N, 5.60.                  Prep 11     Found: C, 74.51; H, 7.22; N, 5.4325  (R)CONHCH(Me)Phg           Et  H  Cmpd of                         126-130                              1 H NMR (CDCl3): δ                              1.06(3H, t, J=7), 1.53(3H, d, J=7),                              1.53-2.21                  Prep 12     (8H, m), 2.65(2H, t, J=7); 3.23(1H, d,                              J=17), 3.67(1H, d, J=17),                              3.89(3H, s), 4.02(2H, t, J=7),                              5.02-5.15(1H, m), 6.85(1H, d, J=8),                              7.02(1H, dd, J=2, 8), 7.16-7.32(12H,                              m)26  (R)CONHCH(Me)Phg           Et  H  Cmpd of                         121-123                              1 H NMR (CDCl3): δ                              0.92(3H, t, J=7), 1.47(3H, d, J=7),                              1.47-2.18                  Prep 12     (8H, m), 2.66(2H, t, J=7), 3.26(1H, d,                              J=17), 3.76(1H, d, J=17),                              3.90(3H, s), 4.04(2H, t, J=7),                              5.02-5.13(1H, m), 6.87(1H, d, J=8),                              7.07(1H, dd, J=2, 8), 7.18-7.36(12H,                              m)27  (R)CONHCH(Me)Phh           Pr  H  Cmpd of                         123-125                              Anal. Calc'd for C33 H40                              N2 O4.1/4 H2 O: C,                              74.27, H, 7.60, N, 5.35.                  Prep 13     Found: C, 74.44; H, 7.50; N, 5.2128  (R)CONHCH(Me)Phi           Pr  H  Cmpd of                         118-120                              Anal. Calc'd for C33 H40                              N2 O4.1/4 H2 O: C,                              74.27; H, 7.60; N, 5.25.                  Prep 13     Found: C, 74.08; H, 7.85; N, 5.1929  OAc         H   H  Vinyl  oil  1 H NMR (CDCl3): δ                              1.46-1.95(6H, m), 2.17(3H, s),                              2.62(2H, t,                  acetate     J=8), 3.30(1H, d, J=18), 3.54-3.60(1H,                              m), 3.87(3H, s), 4.02(2H,                              t, J=7), 5.27(1H, d, J=1),                              6.82-7.30(8H, m)30  CO2 Me NHCO2               H  H2 CH                         oil  1 H NMR (CDCl3): δ                              1.35 -1.84(6H, m), 2.55(2H, t, J=7),                              3.89           Bn     (NHCO2 Bn)                              (3H, s), 3.93(2H, bd s), 3.94(2H, t,                              J=7), 4.01(3H, s), 5.01(2H, s),                  CO2 Me 6.30(1H, bd s), 6.73(1H, d, J=8),                              6.90-7.33(12H, m)__________________________________________________________________________ a trans stereochemistry b less polar diastereomer  Rf 0.23 (1:3 EtOAchexane) c more polar diastereomer  Rf 0.16 (1:3 EtOAchexane) d more polar diastereomer  Rf 0.42 (1:1 EtOAchexane) e less polar diastereomer  Rf 0.48 (1:1 EtOAchexane) f more polar diastereomer  Rf 0.42 (1:1 EtOAchexane) g diastereomers of examples 25 and 26 were separated by fractional crystallization h less polar diastereomer  Rf 0.30 (3:7 EtOAchexane) i more polar diastereomer  Rf 0.26 (3:7 EtOAchexane)
PREPARATIONS 31-32

The following compounds were prepared substantially according to the procedure in Preparation 15 substituting the compound of Preparation 3 for the compound of Preparation 1 and substituting the indicated olefin for ethyl acrylate.

__________________________________________________________________________ ##STR25##Prep #    R5   R4       R3          Olefin M.P. C.                      Data__________________________________________________________________________35  CO2 Et   H   H  Ethyl  oil  1 H NMR (CDCl3): δ 1.27(3H, t,                      J=7), 1.45-2.00(8H, m), 3.56(2H, d,          acrylate    J=10), 3.82(3H, s), 4.22(2H, q, J=7),                      4.72-4.80(1H, m), 5.09(1H, t,                      J=10), 6.78(1H, d, J=8), 6.98(1H, d, J=8),                      7.32(1H, s)32  CO2 Et   Me  H  Ethyl  77-79                      1 H NMR (CDCl3): δ 1.25(3H, t,                      J=7), 1.50-2.00(8H, m), 1.63(3H,          methacrylate                      s), 3.11(1H, d, J=17), 3.78(1H, d, J=17),                      3.91(3H, s), 4.18(2H, q,                      J=7), 4.68-4.77(1H, m), 6.75(1H, d, J=8),                      6.92(1H, dd, J=8, 2),                      7.27(1H, d, J=2)__________________________________________________________________________
PREPARATIONS 33-34

The following compounds were prepared substantially according to the procedure of Preparation 15 substituting the compound of Preparation 4 for the compound of Preparation 1 and substituting the indicated olefin for ethyl acrylate.

__________________________________________________________________________ ##STR26##Prep #    R5     R4              R3                 Olefin M.P. C.                             Data__________________________________________________________________________33  CO2 Et H  H  Ethyl  oil  1 H NMR (CDCl3): δ                             1.05-1.77(8H, m), 1.27(3H, t, J=7),                             2.05(1H,                 acrylate    bd s), 2.43(1H, bd s), 3.55(2H, d,                             J=10), 3.92(3H, s), 4.15-4.23(1H,                             m), 4.21(2H, q, J=7), 5.05(1H, t,                             J=10), 6.77(1H, d, J=8), 6.95(1H,                             d, J=8), 7.25(1H, s)34  (R)CHNHCH(Me)Ph           Me H  Cmpd of                        151-153                             1 H NMR (CDCl3): δ                             1.10-1.75(8H, m), 1.44(3H, d, J=7),                             1.65(3H,                 Prep 11a                             s), 2.30(1H, bd s), 2.50(1H, bd d,                             J=4), 3.18(1H, d, J=17), 3.81(1H,                             d, J=17), 3.85(3H, s), 4.21(1H, d,                             J=7), 4.99-5.08(1H, m), 6.83(1H,                             d, J=8), 7.02(1H, dd, J=8, 2), 7.12(1H,                             d, J=9), 7.20-7.36(6H,__________________________________________________________________________                             m) a less polar diastereomer  Rf 0.4 (3:7 EtOAchexane)
PREPARATION 35 3- 4-Methoxy-3-(5-phenylbutyloxy)!phenyl-2-isoxazoline-5-carboxylic Acid Ethyl Ester

The compound of this Preparation was prepared as an oil, substantially according to the procedure of Preparation 15, substituting the compound of Preparation 2 for the compound of Preparation 1. 1 H NMR (CDCl3): δ 1.31 (3H, t, J=7), 1.74-1.94 (4H, m), 2.68 (2H, t, J=7), 3.57-3.61 (2H, m), 3.87 (3H, s), 4.03 (2H, t, J=6), 4.25 (2H, q, J=7), 5.12 (1H, t, J=8), 6.83 (1H, d, J=8), 7.03 (1H, d, J=8), 7.16-7.35 (6H, m).

PREPARATION 36 Dimethyl Propenyl-2-phosphonate

The title compound was prepared as described by the method of Benezra, et al. (Benezra, C.; Nseic, S.; Qurisson, G. Bull. Chem. Soc. Chim. Fr., 1967, 1140.)

Into a flask fitted with a reflux condenser was placed a mixture of 37 ml (29 g, 0.50 mol) of acetone and 46 ml (55 g, 0.50 ml) of dimethylphosphite followed by 3 ml of saturated methanolic sodium methoxide solution. A vigorous exotherm ensued and the mixture was allowed to stir at RT for about 16 h. A large deposit of crystals formed and were filtered and washed well with ether-hexane (1:1) to give 50 g of dimethyl 1-hydroxy-1-methylethylphosphonate, mp 75-77 C.

A solution of 6.00 g (35.7 mmol) of dimethyl 1-hydroxy-1-methylethyl-phosphonate in 25 ml of pyridine was treated dropwise with 8.56 g (5.25 ml, 72.0 mmol) of thionyl chloride. The mixture was allowed to stir for about 16 h at RT and the solvent was removed by evaporation. The residue was diluted with 200 ml of water and extracted with EtOAc (3200 ml). The combined extracts were dried (Na2 SO4) and evaporated to 4.12 g of a yellow oil which was purified by flash chromatography (100 g of silica gel) using EtOAc as eluant to yield 3.46 g of the title compound as an oil.

PREPARATION 37 Diethyl 2-Methyl-1-propenyl-3-phosphonate

A mixture of 5.0 g (0.037 mol) of methallyl bromide and 15 g (0.087 mol) of triethyl phosphite was heated to about 160 C. for about 5 h. Purification of the crude reaction mixture by flash chromatography (300 g of silica gel) using an EtOAc-hexane (3:2) eluant afforded 3.6 g (50%) of the title compound as a light yellow oil. 1 H NMR (CDCl3): d 1.31 (6H, t, J=7), 1.87 (3H, d, J=3), 2.56 (2H, d, J=20), 4.03-4.13 (4H, m), 4.82-4.92 (2H, m).

PREPARATION 38 Diethyl 3- 4-Methoxy-3-(5-phenylpentyloxy)!phenyl-2-isoxazolin-5-ylphosphonate

To a mixture of 1.02 g (7.76 mmol) of N-chlorosuccinimide, 0.05 ml of pyridine, and 30 ml of CH3 Cl2 was added 2.00 g (6.38 mmol) of the compound Preparation 1 in 10 ml of CH2 Cl2. The mixture was stirred for about 45 min at RT and 1.05 g (0.980 ml, 6.38 mmol) of diethyl vinylphosphonate was added followed by 0.777 g (1.07 ml, 7.66 mmol) of triethylamine. An exotherm ensued and the mixture became dark yellow. After stirring for about 2 h at RT, the mixture was diluted to 150 ml with CH2 Cl2 and was washed with aqueous 1N HCl solution (2100 ml), sat'd. aqueous NaHCO3 solution (2100 ml), dried (MgSO4), and evaporated to 3.75 g of a yellow oil. Purification by flash chromatography (150 g of silica gel) using successively EtOAc-hexane (1:3), EtOAc, and MeOH--CHCl3 (1:9) as eluants afforded 1.09 g of the title compound as an oil. 1 H NMR (CDCl3): d 1.30 (3H, t, J=7), 1.34 (3H, t, J=7), 1.40-1.90 (6H, m), 2.60 (2H, t, J=7), 3.52-3.65 (2H, m), 3.95 (3H, s), 3.99 (2H, t, J=7), 4.16-4.25 (4 H, m), 4.80 (1H, t, J=12), 6.80 (1H, d, J=8), 6.98-7.29 (7H, m).

PREPARATION 39-42

Reaction of the indicated oxime and olefin, analogous to the procedure of Preparation 38, afforded compounds having the following general structure: ##STR27##

39. R2 is (CH2)5 Ph; R4 is methyl; R5 is methyl; s is 0; the oxime is the compound of Preparation 1; the olefin is the compound of Preparation 36; M.P. 91-93 C.; 1 H NMR (CDCl3): d 1.46-1.92 (6H, m), 1.64 (3H, d, J=15), 2.62 (2H, t, J=7), 3.18 (1H, dd, J=17 and 19), 3.75-3.88 (10H, m), 4.00 (2H, t, J=7), 6.83 (1H, d, J=8), 7.00 (1H, d, J=8, 2), 7.14-7.33 (6H, m).

40. R2 is (CH2)5 Ph; R4 is H; R5 is ethyl; s is 1; the oxime is the compound of Preparation 1; the olefin is diethyl allylphosphonate; 1 H NMR (CDCl3): d 1.32 (3H, t, J=7), 1.34 (3H, t, J=7), 1.37-2.38 (8H, m), 2.61 (2H, t, J=7), 3.22 -3.52 (2H, m), 3.86(3H, s), 4.00 (2H, t, J=7), 4.06-4.18 (4H, m), 4.82-4.96 (1H, m), 6.82 (1H, d, J=8), 7.03 (1H, dd, J=2, 8), 7.13-7.33 (6H, m).

41. R2 is (CH2)5 Ph; R4 is methyl; R5 ethyl; s is 1; the oxime is the compound of Preparation 1; the olefin is the compound of Preparation 37; 1 H NMR (CDCl3): d 1.30 (3H, t, J=7), 1.32 (3H, t, J=7), 1.28-1.90 (6H, m), 2.30 (2H, d, J=19), 2.61 (2H, t, J=7), 3.08 (1H, d, J=17), 3.63 (1H, d, J=17), 3.86 (3H, s), 4.00 (2H, t, J=7 ), 4.00-4.18 (4H, m), 6.82 (1H, d, J=8), 6.99 (1H, dd, J=2, 8), 7.11-7.32 (6H, m).

42. R2 is cyclopentyl; R4 is H; R5 is ethyl, s is 0, the oxime is the compound of Preparation 3; the olefin is diethyl vinylphosphonate; 1 H NMR (CDCl3): d 1.31 (3H, t, J=7), 1.35 (3H, t, J=7), 1.50-2.00 (8H, m), 3.56-3.67 (2H, m), 3.85 (3 H, s), 4.17-4.25 (4H, m), 4.78-4.82 (2H, m), 6.83 (1H, d, J=8), 7.02 (1H, dd, J=2, 8), 7.32 (1H, d, J=2).

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4889551 *Sep 2, 1987Dec 26, 1989Mitsui Toatsu Chemicals, IncorporatedIsoxazoline derivatives and plant growth regulators
US4912120 *Mar 13, 1987Mar 27, 1990Syntex (U.S.A.) Inc.3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
US4924002 *Feb 13, 1989May 8, 1990Warner-Lambert CompanyNovel process for the preparation of pyrazoles from isoxazoles
US4933464 *Apr 25, 1988Jun 12, 1990W. R. Grace & Co.-Conn.Process for forming 3-phenylisoxazolines and 3-phenylisoxazoles
US4952700 *Apr 25, 1988Aug 28, 1990W.R. Grace & Co.-Conn.Preparation of isoxazolines and isoxazoles
US5006515 *Oct 26, 1988Apr 9, 1991Hoechst AktiengesellschaftPharmaceuticals, phosphorus-containing 2-isoxazolines and isoxazoles contained therein
US5208251 *Aug 16, 1989May 4, 1993Warner-Lambert CompanyStyryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors, pharmaceutical compositions and methods of use therefor
US5273989 *Apr 10, 1991Dec 28, 1993Hoechst Aktiengesellschaft3,5-disubstituted 2-isoxazolines and isoxazoles, agents containing them and their use
EP0247725A2 *Apr 23, 1987Dec 2, 1987Pfizer Inc.Calcium independent camp phosphodiestrerase inhibitor antidepressant
EP0401903A2 *May 30, 1990Dec 12, 1990THE PROCTER & GAMBLE COMPANYThe use of vanilloids for the treatment of respiratory diseases or disorders
WO1987006576A1 *Apr 29, 1986Nov 5, 1987Pfizer Inc.Calcium independent camp phosphodiesterase inhibitor antidepressant
WO1991007178A1 *Apr 20, 1990May 30, 1991Pfizer Inc.Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
WO1991015451A1 *Apr 2, 1991Oct 17, 1991Smithkline Beecham Pharma GmbhNovel derivatives of phenyl-cycloalkanes and -cycloalkenes
WO1992003053A1 *Aug 8, 1991Mar 5, 1992Hoechst AktiengesellschaftPlant protecting agents containing isoxazoline or isothiazoline and new isoxazolines and isothiazolines
WO1992007567A1 *Nov 5, 1991May 14, 1992Smithkline Beecham CorporationImidazolidinone compounds
WO1992019594A1 *May 1, 1992Nov 12, 1992Smithkline Beecham CorporationPyrrolidinones
WO1993007141A1 *Oct 2, 1992Apr 15, 1993Smithkline Beecham CorporationHeterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
Non-Patent Citations
Reference
1 *0039867: Japan, Derwent Publication Abstract, No. 88 088442/13, Feb. 1988.
20039867: Japan, Derwent Publication Abstract, No. 88-088442/13, Feb. 1988.
3 *C. D. Nicholson et al., TiPS, Jan. 1991, vol. 12, pp. 19 27.
4C. D. Nicholson et al., TiPS, Jan. 1991, vol. 12, pp. 19-27.
5 *CA 103: 160616d, Nishiyama et al., p. 123, 1985.
6 *CA 113: 58998z, Jarrar et al., p. 687, 1990.
7 *CA 96:84853y, Kumagai et al., p. 527, 1982.
8 *E. W. Sutherland et al., Pharmacol. Rev., 1960, 12, pp. 265 299.
9E. W. Sutherland et al., Pharmacol. Rev., 1960, 12, pp. 265-299.
10 *J. A. Beavo et al., TiPS, Apr. 1990, vol. 11, pp. 150 155.
11J. A. Beavo et al., TiPS, Apr. 1990, vol. 11, pp. 150-155.
12 *J. Am. Chem. Soc., 107, pp. 5310 5312, Nishiyama et al., 1985.
13J. Am. Chem. Soc., 107, pp. 5310-5312, Nishiyama et al., 1985.
14 *J. Heterocyclic Chem., 27, pp. 275 278, Jarrar et al., 1990.
15J. Heterocyclic Chem., 27, pp. 275-278, Jarrar et al., 1990.
16 *M. W. Verghese et al., J. Mol. Cell Cardiol., 1989, 12 (Suppl. II), S61.
17 *Tetrahedron, vol. 37, No. 19, pp. 3365 3376, Kumagi et al., 1981.
18Tetrahedron, vol. 37, No. 19, pp. 3365-3376, Kumagi et al., 1981.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6469176 *Nov 12, 1999Oct 22, 2002Basf AktiengesellschaftMethod and novel intermediate products for producing isoxazolin-3-yl-acylbenzenenes
US6608209Jun 27, 2002Aug 19, 2003Basf AktiengesellschaftPreparation of isoxazolin-3-ylacylbenzenes
US6706886May 14, 2003Mar 16, 2004Basf AktiengesellschaftProcess and novel intermediates for preparing isoxazolin-3-ylacyl benzenes
US6747050Sep 18, 2000Jun 8, 2004Lg Chem Investment Ltd.Isoxazoline derivative and a process for the preparation thereof
US7309802Apr 17, 2003Dec 18, 2007Basf AktiengesellschaftPreparation of isoxazolin-3-ylacylbenzene
US7663001Mar 11, 2007Feb 16, 2010Basf AktiengesellschaftPreparation of isoxazolin-3-ylacylbenzene
US7678808May 8, 2007Mar 16, 2010Braincells, Inc.5 HT receptor mediated neurogenesis
US7825147 *Aug 30, 2004Nov 2, 2010Ranbaxy Laboratories LimitedInhibitors of phosphodiesterase type-IV
US7985756Oct 20, 2006Jul 26, 2011Braincells Inc.Modulation of neurogenesis by PDE inhibition
US7998971Jun 21, 2007Aug 16, 2011Braincells Inc.Combinations containing a 4-acylaminopyridine derivative
US8049017Mar 2, 2011Nov 1, 2011Basf SePreparation of isoxazolin-3-ylacylbenzenes
US8124810Jan 4, 2010Feb 28, 2012Basf SePreparation of isoxazolin-3-ylacylbenzenes
US20030216580 *Apr 17, 2003Nov 20, 2003Joachim RheinheimerPreparation of Isoxazolin-3-Ylacylbenzene
US20050075383 *Aug 30, 2004Apr 7, 2005Palle Venkata P.Inhibitors of phophodiesterase type-IV
US20070161800 *Mar 11, 2007Jul 12, 2007Joachim RheinheimerPreparation of Isoxazolin-3-Ylacylbenzene
US20070259874 *Nov 26, 2004Nov 8, 2007Palle Venkata PPhosphodiesterase Inhibitors
US20080064671 *Jun 21, 2007Mar 13, 2008Braincells, Inc.Combinations containing a 4-acylaminopyridine derivative
US20080113997 *May 1, 2007May 15, 2008Cytokine Pharmasciences, Inc.Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
US20090054382 *Oct 19, 2006Feb 26, 2009Abhijit RayCompositions of phosphodiesterase type iv inhibitors
US20100105920 *Jan 4, 2010Apr 29, 2010Joachim RheinheimerPreparation of isoxazolin-3-ylacylbenzenes
US20110152535 *Mar 2, 2011Jun 23, 2011Joachim RheinheimerPreparation of isoxazolin-3-ylacylbenzenes
CN101006065BJun 17, 2005Jul 11, 2012英菲尼蒂发现公司Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
EP2147679A2Jul 25, 2002Jan 27, 2010Raptor Pharmaceutical Inc.Compositions and methods for modulating blood-brain barrier transport
EP2258357A2Aug 25, 2006Dec 8, 2010Braincells, Inc.Neurogenesis with acetylcholinesterase inhibitor
EP2258358A2Aug 25, 2006Dec 8, 2010Braincells, Inc.Neurogenesis with acetylcholinesterase inhibitor
EP2258359A2Aug 25, 2006Dec 8, 2010Braincells, Inc.Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A2Aug 25, 2006Jan 19, 2011Braincells, Inc.Neurogenesis by muscarinic receptor modulation
EP2275096A2Aug 25, 2006Jan 19, 2011Braincells, Inc.Neurogenesis via modulation of the muscarinic receptors
EP2314289A1Oct 30, 2006Apr 27, 2011Braincells, Inc.Gaba receptor mediated modulation of neurogenesis
EP2377530A2Oct 20, 2006Oct 19, 2011Braincells, Inc.Modulation of neurogenesis by PDE inhibition
EP2377531A2May 9, 2007Oct 19, 2011Braincells, Inc.Neurogenesis by modulating angiotensin
EP2382975A2May 9, 2007Nov 2, 2011Braincells, Inc.Neurogenesis by modulating angiotensin
EP2392258A1Apr 28, 2006Dec 7, 2011Proteus Biomedical, Inc.Pharma-informatics system
WO2001021600A1 *Sep 18, 2000Mar 29, 2001Lg Chem Investment Ltd.Caspase inhibitor
WO2006116718A2Apr 28, 2006Nov 2, 2006Proteus Biomedical, Inc.Pharma-informatics system
WO2007045980A1 *Oct 19, 2006Apr 26, 2007Ranbaxy Laboratories LimitedCompositions of phosphodiesterase type iv inhibitors
WO2008035316A2 *Sep 22, 2007Mar 27, 2008Ranbaxy Laboratories LimitedPhosphodiesterase inhibitors
WO2008035316A3 *Sep 22, 2007Nov 27, 2008Sarala BalachandranPhosphodiesterase inhibitors
WO2008036682A2Sep 18, 2007Mar 27, 2008Raptor Pharmaceutical Inc.Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2010095940A2Feb 19, 2010Aug 26, 2010To-Bbb Holding B.V.Glutathione-based drug delivery system
WO2010099217A1Feb 24, 2010Sep 2, 2010Braincells, Inc.Modulation of neurogenesis using d-cycloserine combinations
WO2011063115A1Nov 18, 2010May 26, 2011Braincells Inc.Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1Jan 19, 2011Jul 28, 2011Braincells, Inc.Modulation of neurogenesis by ppar agents
WO2012044761A1Sep 29, 2011Apr 5, 2012University Of North Carolina At WilmingtonLadder-frame polyether conjugates
WO2013106547A1Jan 10, 2013Jul 18, 2013President And Fellows Of Harvard CollegeBeta-cell replication promoting compounds and methods of their use
Classifications
U.S. Classification514/92, 548/245, 514/379, 548/243, 514/378, 548/119, 514/380, 548/111, 548/240, 548/113, 548/242, 548/244
International ClassificationC07D261/08, C07D498/04, A61P11/00, A61P37/08, C07F9/6561, C07D261/04, A61P17/00, C07F9/653, C07D261/18, A61P31/12, A61P43/00, A61P29/00, A61P31/18, A61K31/41, A61K31/675, A61K31/42
Cooperative ClassificationC07D261/04, C07F9/653
European ClassificationC07F9/653, C07D261/04
Legal Events
DateCodeEventDescription
Dec 7, 1999CCCertificate of correction
Mar 9, 2001FPAYFee payment
Year of fee payment: 4
Mar 29, 2005FPAYFee payment
Year of fee payment: 8
May 18, 2009REMIMaintenance fee reminder mailed
Nov 11, 2009LAPSLapse for failure to pay maintenance fees
Dec 29, 2009FPExpired due to failure to pay maintenance fee
Effective date: 20091111